---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-009259"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:48:53.312344+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q4 revenue up 42% YoY to $2.3M; net loss narrows to $1.9M

## Summary
- Q4 revenue $2.3M (+42% YoY); full-year revenue $8.5M (+8% YoY). Gross margin 56.9% (+250 bps).
- Net loss $1.9M ($5.00/share) vs $4.3M loss prior year; includes $2.6M other income from warrant revaluation.
- Cash $18.3M, no debt; outstanding shares ~1.2M after reverse split and warrant exercises.
- Entered exclusive U.S. license for SeaStar Medical's SCD for pediatric AKI; clinical data published supporting Aquadex.
- Board increased inducement plan shares by 44,078 to 46,928 to attract talent.

## SEC filing metadata
- accession: 0001140361-23-009259
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/brhc10049033_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-009259
- JSON: https://secwatch.observer/filing/0001140361-23-009259.json
- Plain text: https://secwatch.observer/filing/0001140361-23-009259.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported the twelve months ended December 31, 2022 results: revenue $8.5 million.
  - Period: the twelve months ended December 31, 2022
  - Revenue: $8.5 million
  - Result: reported results
  source text: Full year revenue of $8.5 million, an 8% increase over 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm
- Earnings Releases
  Nuwellis, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $2.3 million, net income $1.9 million, EPS loss of $5.00 per basic and diluted common share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $2.3 million
  - Net income: $1.9 million
  - EPS: loss of $5.00 per basic and diluted common share
  - Result: reported results
  source text: Revenue for the fourth quarter of 2022 was $2.3 million, compared to $1.6 million in the prior-year period. Gross margin was 56.9% for the fourth quarter of 2022, compared to 54.4% in the prior-year period, an increase of 250 basis points, resulting from increased sales volume. Selling, general and administrative expenses for the fourth quarter of 2022 were $4.7 million, compared to $4.1 million in the prior-year period. The increase in SG&A was primarily due to higher professional service fees and variable compensation expense, balanced with continued spending vigilance. Fourth quarter research and development expenses were $1.2 million, compared to $1.1 million in the fourth quarter of 2021, reflecting a slight increase in product development expenses . Net loss for the fourth quarter of 2022 was $1.9 million, or a loss of $5.00 per basic and diluted common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.